PE20080124A1 - Formulaciones de aerosol que contiene ester s-fluorometilico de 6alfa,9alfa-difluoro-17alfa[(2-furanilcarbonil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta,1,4-dieno-17beta-carbotioico - Google Patents

Formulaciones de aerosol que contiene ester s-fluorometilico de 6alfa,9alfa-difluoro-17alfa[(2-furanilcarbonil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta,1,4-dieno-17beta-carbotioico

Info

Publication number
PE20080124A1
PE20080124A1 PE2007000310A PE2007000310A PE20080124A1 PE 20080124 A1 PE20080124 A1 PE 20080124A1 PE 2007000310 A PE2007000310 A PE 2007000310A PE 2007000310 A PE2007000310 A PE 2007000310A PE 20080124 A1 PE20080124 A1 PE 20080124A1
Authority
PE
Peru
Prior art keywords
androste
9alpha
6alpha
dieno
17alpha
Prior art date
Application number
PE2007000310A
Other languages
English (en)
Spanish (es)
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
Glaxo Group Ltd
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, 3M Innovative Properties Co filed Critical Glaxo Group Ltd
Publication of PE20080124A1 publication Critical patent/PE20080124A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PE2007000310A 2006-03-22 2007-03-21 Formulaciones de aerosol que contiene ester s-fluorometilico de 6alfa,9alfa-difluoro-17alfa[(2-furanilcarbonil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta,1,4-dieno-17beta-carbotioico PE20080124A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
PE20080124A1 true PE20080124A1 (es) 2008-04-21

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000310A PE20080124A1 (es) 2006-03-22 2007-03-21 Formulaciones de aerosol que contiene ester s-fluorometilico de 6alfa,9alfa-difluoro-17alfa[(2-furanilcarbonil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta,1,4-dieno-17beta-carbotioico

Country Status (18)

Country Link
EP (1) EP2012797A2 (ru)
JP (1) JP2009530419A (ru)
KR (1) KR20080110854A (ru)
CN (1) CN101415428A (ru)
AR (1) AR060039A1 (ru)
AU (1) AU2007226899A1 (ru)
BR (1) BRPI0708798A2 (ru)
CA (1) CA2646236A1 (ru)
CR (1) CR10261A (ru)
EA (1) EA200801854A1 (ru)
IL (1) IL193723A0 (ru)
MA (1) MA30328B1 (ru)
MX (1) MX2008011967A (ru)
NO (1) NO20083760L (ru)
PE (1) PE20080124A1 (ru)
TW (1) TW200803870A (ru)
WO (1) WO2007109698A2 (ru)
ZA (1) ZA200807682B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578169B1 (en) * 2009-02-26 2024-06-26 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689424B1 (en) * 1993-03-17 1998-10-14 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
WO2002012265A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT

Also Published As

Publication number Publication date
BRPI0708798A2 (pt) 2011-06-14
EA200801854A1 (ru) 2009-04-28
WO2007109698A2 (en) 2007-09-27
CR10261A (es) 2008-11-26
AR060039A1 (es) 2008-05-21
CA2646236A1 (en) 2007-09-27
JP2009530419A (ja) 2009-08-27
AU2007226899A1 (en) 2007-09-27
EP2012797A2 (en) 2009-01-14
MX2008011967A (es) 2009-01-14
KR20080110854A (ko) 2008-12-19
CN101415428A (zh) 2009-04-22
NO20083760L (no) 2008-12-17
IL193723A0 (en) 2009-08-03
TW200803870A (en) 2008-01-16
ZA200807682B (en) 2009-11-25
MA30328B1 (fr) 2009-04-01
WO2007109698A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
ES2717204T3 (es) Compuestos aminoesteroideos para una aplicación tópica local para la descolonización cutáneo-mucosa de Staphylococcus aureus
WO2021102411A8 (en) Ionizable lipids and nanoparticle compositions thereof
US9050293B2 (en) Small molecule solubilization system
JP2007530573A5 (ru)
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BRPI0608690A2 (pt) uso de uma composição antimicrobiana
EA200802444A1 (ru) Стабилизированные фармацевтические композиции, содержащие фезотеродин
EP1300412A4 (en) HYALURONIC ACID OLIGOSACCHARIDE FACTIONS AND MEDICINES THAT CONTAIN THEM
KR20060118443A (ko) 항미생물성 조성물 및 방법
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
DE602006004451D1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
ECSP088240A (es) Composición de trazodona para administración una vez por día
NZ602538A (en) Thermogelling anaesthetic compositions
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
DE102014009164A1 (de) Silikonölhaltige nasal anzuwendende Formulierungen
BRPI0915119B8 (pt) uso de iota carragenano
CN107106445A (zh) 泡沫喷出容器装的液体口腔用组合物
ES2860098T3 (es) Composición para la aplicación nasal
PE20080124A1 (es) Formulaciones de aerosol que contiene ester s-fluorometilico de 6alfa,9alfa-difluoro-17alfa[(2-furanilcarbonil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta,1,4-dieno-17beta-carbotioico
BR112015013689A2 (pt) composições fluidas de cuidado oral contendo peróxido
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
PE17897A1 (es) Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
TW200930381A (en) Compositions and methods for the treatment of bladder cancer

Legal Events

Date Code Title Description
FD Application declared void or lapsed